From June 16 to 18, 2026, the 24th International Exhibition on Pharmaceutical Ingredients (CPHI China) and the 19th International Exhibition on Pharmaceutical Machinery, Packaging Equipment, and Materials (PMEC China) were successfully held at the Shanghai New International Expo Center (Pudong). As Asia's premier pharmaceutical industry event and a benchmark annual gathering for the global pharmaceutical community, this year's exhibition reached new heights of scale and impact. With a total exhibition area of 250,000 square meters, the event brought together 3,701 leading companies from around the world and attracted 129,172 professional visitors from 168 countries and regions, including the United States, Canada, Germany, Italy, Spain, the United Kingdom, France, Australia, Brazil, India, South Korea, Japan, and many others. Overseas visitors accounted for over 25% of total attendance, underscoring the exhibition's growing role as a global hub for the pharmaceutical supply chain and its expanding international influence.
Under the theme "Collaborative Innovation, Smart Future for Pharmaceuticals," the exhibition systematically covered 13 pharmaceutical sub-sectors, including pharmaceutical ingredients, natural products, biotechnology, pharmaceutical excipients, pharmaceutical outsourcing services, formulations, pharmaceutical machinery and packaging equipment, packaging and drug delivery systems, laboratory instruments and equipment, cleanroom equipment and engineering, environmental protection and energy-saving equipment, bioengineering, and life science instruments . Six new themed zones were also introduced, including the International New Brand Zone, Smart Laboratory Space, and Advanced Technology and Innovative Therapy Showcase Area . The event featured over 100 concurrent conference sessions and activities, providing a comprehensive platform for industry networking, technology exchange, and business collaboration .
As an innovative enterprise dedicated to the independent R&D and production of high-end domestic assay reagents, Shanghai VKEY Biotechnologies Co.,Ltd. made its debut at CPHI China 2026, showcasing its capabilities in the Biotechnology Zone-Hall W9 (Biotech Hall) at Booth W9A86 . Founded in 2019 and headquartered in Shanghai, VKEY-BIO has established itself as a trusted provider of high-performance, cost-effective bioassay kits, earning recognition as an "Innovative SME" and a "Technology-based SME" .
Throughout the three-day exhibition, the VKEY-BIO booth attracted a steady stream of visitors, including pharmaceutical R&D professionals, industry experts, and decision-makers from both domestic and international companies. The company's technical experts engaged in one-on-one discussions with attendees, sharing insights on how high-quality domestic assay kits can reduce drug discovery costs and accelerate R&D timelines.
VKEY-BIO highlighted its two core technology platforms:
KeyTec® Luminescent Series: A comprehensive suite of luminescence-based assay solutions, featuring higher sensitivity and extended half-life, designed for cell viability assays, reporter gene assays, and in vivo small animal imaging studies .
KeyTec® TR-FRET Technology Platform: A time-resolved fluorescence resonance energy transfer system based on lanthanide fluorescent donors and acceptors, suitable for a wide range of applications including protein-protein interaction studies, enzymatic research, GPCR pathway analysis, tumor immunology, and antibody development . The platform is built on independently developed lanthanide fluorescent molecules such as Solar Eu and Bright Tb, offering flexible options with distinct characteristics in fluorescence intensity, water solubility, and pH tolerance.
Visitors to the booth had the opportunity to learn about VKEY-BIO's growing portfolio of biochemical assay kits, including kinase activity assays, protein interaction detection systems, PROTAC screening tools, and GPCR‑related research solutions .
To express gratitude to its customers and partners, VKEY-BIO organized a series of interactive activities at the booth. Attendees who visited the booth, scanned the QR code to follow the official WeChat account, and completed a product needs questionnaire or engaged in technical discussions with the experts were eligible to participate in a lucky draw. The response was overwhelmingly positive, with many visitors expressing strong interest in VKEY-BIO's product offerings and technical capabilities.
The company's commitment to quality, innovation, and customer support resonated with the professional audience, generating numerous inquiries and promising leads for future collaboration.
The successful debut at CPHI & PMEC China 2026 marked an important milestone for VKEY BIO. The exhibition not only provided a valuable platform for showcasing the company's technological capabilities but also offered an opportunity to listen to customer needs, understand industry trends, and strengthen connections with partners across the pharmaceutical value chain.
English
